Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Asset Writedowns and Impairment (2022 - 2024)

Historic Asset Writedowns and Impairment for ProPhase Labs (PRPH) over the last 5 years, with Q4 2024 value amounting to $11.0 million.

  • ProPhase Labs' Asset Writedowns and Impairment rose 18353333.33% to $11.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.0 million, marking a year-over-year increase of 142182.32%. This contributed to the annual value of $11.0 million for FY2024, which is 142182.32% up from last year.
  • As of Q4 2024, ProPhase Labs' Asset Writedowns and Impairment stood at $11.0 million, which was up 18353333.33% from $6000.0 recorded in Q4 2023.
  • ProPhase Labs' Asset Writedowns and Impairment's 5-year high stood at $11.0 million during Q4 2024, with a 5-year trough of -$3.3 million in Q4 2022.
  • Over the past 3 years, ProPhase Labs' median Asset Writedowns and Impairment value was $273000.0 (recorded in 2022), while the average stood at $1.4 million.
  • Per our database at Business Quant, ProPhase Labs' Asset Writedowns and Impairment plummeted by 7029.53% in 2023 and then surged by 18353333.33% in 2024.
  • Over the past 3 years, ProPhase Labs' Asset Writedowns and Impairment (Quarter) stood at -$3.3 million in 2022, then surged by 100.18% to $6000.0 in 2023, then surged by 183533.33% to $11.0 million in 2024.
  • Its Asset Writedowns and Impairment stands at $11.0 million for Q4 2024, versus $6000.0 for Q4 2023 and $865000.0 for Q2 2023.